Cost-effectiveness of acarbose for the management of impaired glucose tolerance in Sweden.
We assessed the cost-effectiveness of acarbose in the management of patients with impaired glucose tolerance (IGT) in Sweden, based on progression to type 2 diabetes (T2D) and cardiovascular (CV) events reported in the STOP-NIDDM trial population, including high-risk subgroups. The cost per patient free from T2D was SEK28,000 or SEK1260 per diabetes free month prior to progression to T2D. The cost per patient free from CV events was SEK101,000 or SEK5000 per CV event free month. For the high CV risk subgroups, acarbose treatment dominated placebo (i.e. acarbose was more effective, less costly). Acarbose significantly reduces the incidence of diabetes and CV events in IGT patients. We predict this may translate into healthcare cost savings that partially or, in patients at high CV risk, fully offset the cost of acarbose. We conclude that acarbose is likely to be cost-effective in the management of impaired glucose tolerance.
Quilici
S
S
Innovus Research (UK) Ltd, High Wycombe, UK.
Chancellor
J
J
Maclaine
G
G
McGuire
A
A
Andersson
D
D
Chiasson
J-L
JL
D020909:Acarbose / Q000191:economics / Q000627:therapeutic use*; D000368:Aged; D002318:Cardiovascular Diseases / Q000191:economics / Q000517:prevention & control; D003362:Cost-Benefit Analysis; D003924:Diabetes Mellitus, Type 2 / Q000191:economics / Q000517:prevention & control; D005260:Female; D018149:Glucose Intolerance / Q000188:drug therapy* / Q000191:economics; D005951:Glucose Tolerance Test; D017048:Health Care Costs / Q000706:statistics & numerical data*; D006801:Humans; D007004:Hypoglycemic Agents / Q000191:economics / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013548:Sweden
D007004:Hypoglycemic Agents; D020909:Acarbose